IP Library Granted Patent US 10,494,607
Granted Patent B2
US 10,494,607 · App. 12/030,170 · Granted Dec 3, 2019

CD34

Inventors: James W. Edinger (Belford, NJ); Robert J. Hariri (Florham Park, NJ); Jia-Lun Wang (Cherry Hill, NJ); Qian Ye (Livingston, NJ); Marian Pereira (Cranford, NJ); Sascha Dawn Abramson (Hillsborough, NJ); Kristen S. Labazzo (Springfield, NJ)
Assignee: CELULARITY, INC.
C12N5/067A01K67/0271C12N5/0605C12N5/0607C12N5/0655A01K2267/0337A61K2035/128C12N2500/30C12N2500/36C12N2500/62C12N2501/15C12N2501/999C12N2506/02C12N2506/03C12N2533/32C12N2533/40C12N2533/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,494,607
App. No.
12/030,170
Granted
Dec 3, 2019
Kind
B2
Abstract

Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34 + CD45 − stem cells from placenta.

Claims (5)

1. A method of producing an isolated CD34 + , CD45 − hematopoietic placental stem cell population, comprising selecting CD34 + cells from a population of placental cells using antibodies to form a population of CD34 + placental cells, removing from said population of CD34 + placental cells CD45 + cells using antibodies, and combining the resulting cells with a physiologically-acceptable aqueous saline solution, wherein a CD34 + , CD45 − hematopoietic placental stem cell population is produced.

2. The method of claim 1 , wherein said population produces CFU-E or BFU-E when cultured in vitro.

3. The method of claim 1 , wherein at least 50% of cells in said population are CD34 + , CD45 − .

4. The method of claim 1 , wherein at least 70% of cells in said population are CD34 + , CD45 − .

5. The method of claim 1 , wherein at least 90% of cells in said population are CD34 + , CD45 − .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2008
From: EDINGER, JAMES W.; HARIRI, ROBERT J.; WANG, JIA-LUN; YE, QIAN; PEREIRA, MARIAN; ABRAMSON, SASCHA DAWN; LABAZZO, KRISTEN S.
To: ANTHROGENESIS CORPORATION
Reel/Frame 021128/0504 →
Cited By (4)
US 12,352,679 US 12,379,387 US 12,461,007 US 12,551,509